Microbiota-Driven Mechanisms in Multiple Sclerosis: Pathogenesis, Therapeutic Strategies, and Biomarker Potential DOI Creative Commons
Mohammad Hossein Nemati,

Esmaeil Yazdanpanah,

Roya Kazemi

et al.

Biology, Journal Year: 2025, Volume and Issue: 14(4), P. 435 - 435

Published: April 17, 2025

Multiple sclerosis (MS) is a well-known, chronic autoimmune disorder of the central nervous system (CNS) involving demyelination and neurodegeneration. Research previously conducted in area gut microbiome has highlighted it as critical contributor to MS pathogenesis. Changes commensal microbiota, or dysbiosis, have been shown affect immune homeostasis, leading elevated levels pro-inflammatory cytokines disruption gut–brain axis. In this review, we provide comprehensive overview interactions between microbiota MS, especially focusing on immunomodulatory actions such influencing T-cell balance control metabolites, e.g., short-chain fatty acids. Various microbial taxa (e.g., Prevotella Faecalibacterium) were suggested lay protective roles, whereas Akkermansia muciniphila was associated with disease aggravation. Interventions including probiotics, prebiotics, fecal transplantation (FMT), dietary therapies normalize suppress inflammation are proven improve clinical benefits patients. Alterations represent opportunities for identifying biomarkers early diagnosis, progression treatment response monitoring. Further studies need be potentially address interplay genetic predispositions, environmental cues, composition get precise mechanisms axis MS. conclusion, plays role pathogenesis offers potential novel therapeutic approaches, providing promising avenue improving outcomes management.

Language: Английский

Microbiota-Driven Mechanisms in Multiple Sclerosis: Pathogenesis, Therapeutic Strategies, and Biomarker Potential DOI Creative Commons
Mohammad Hossein Nemati,

Esmaeil Yazdanpanah,

Roya Kazemi

et al.

Biology, Journal Year: 2025, Volume and Issue: 14(4), P. 435 - 435

Published: April 17, 2025

Multiple sclerosis (MS) is a well-known, chronic autoimmune disorder of the central nervous system (CNS) involving demyelination and neurodegeneration. Research previously conducted in area gut microbiome has highlighted it as critical contributor to MS pathogenesis. Changes commensal microbiota, or dysbiosis, have been shown affect immune homeostasis, leading elevated levels pro-inflammatory cytokines disruption gut–brain axis. In this review, we provide comprehensive overview interactions between microbiota MS, especially focusing on immunomodulatory actions such influencing T-cell balance control metabolites, e.g., short-chain fatty acids. Various microbial taxa (e.g., Prevotella Faecalibacterium) were suggested lay protective roles, whereas Akkermansia muciniphila was associated with disease aggravation. Interventions including probiotics, prebiotics, fecal transplantation (FMT), dietary therapies normalize suppress inflammation are proven improve clinical benefits patients. Alterations represent opportunities for identifying biomarkers early diagnosis, progression treatment response monitoring. Further studies need be potentially address interplay genetic predispositions, environmental cues, composition get precise mechanisms axis MS. conclusion, plays role pathogenesis offers potential novel therapeutic approaches, providing promising avenue improving outcomes management.

Language: Английский

Citations

0